Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.medmal.2020.04.006 http://scihub22266oqcxt.onion/10.1016/j.medmal.2020.04.006 32305563!7162775!32305563     free     free     free       Med+Mal+Infect 2020 ; 50 (5): 436-439 Nephropedia Template TP {{tp|p=32305563|t=2020. Features of anosmia in COVID-19 |pdf=|usr=}}{{32305563}} gab.com Text Features of anosmia in COVID-19 JO: Med Mal Infect http://www.kidney.de/pget.php?&tw=1&pmid=32305563 #FOAvip BACKGROUND: Medical publications about anosmia with COVID-19 are scarce. We aimed to describe the prevalence and features of anosmia in COVID-19 patients. METHODS: We retrospectively included COVID-19 patients with anosmia between March 1st and March 17th, 2020. We used SARS-CoV-2 real time PCR in respiratory samples to confirm the cases. RESULTS: Fifty-four of 114 patients (47%) with confirmed COVID-19 reported anosmia. Mean age of the 54 patients was 47 (+/-16) years; 67% were females and 37% were hospitalised. The median Charlson comorbidity index was 0.70 (+/-1.6 [0-7]). Forty-six patients (85%) had dysgeusia and 28% presented with pneumonia. Anosmia began 4.4 (+/-1.9 [1-8]) days after infection onset. The mean duration of anosmia was 8.9 (+/-6.3 [1-21]) days and 98% of patients recovered within 28 days. CONCLUSIONS: Anosmia was present in half of our European COVID-19 patients and was often associated with dysgeusia. Twit Text FOAVip Features of anosmia in COVID-19 ????Med Mal Infect http://www.kidney.de/pget.php?&tw=1&pmid=32305563 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32305563 #FOAvip English Wikipedia <ref>{{Cite pmid|32305563}}</ref> Features of anosmia in COVID-19 #MMPMID32305563 Klopfenstein T; Kadiane-Oussou NJ; Toko L; Royer PY; Lepiller Q; Gendrin V; Zayet S Med Mal Infect 2020[Aug]; 50 (5): 436-439 PMID32305563show ga BACKGROUND: Medical publications about anosmia with COVID-19 are scarce. We aimed to describe the prevalence and features of anosmia in COVID-19 patients. METHODS: We retrospectively included COVID-19 patients with anosmia between March 1st and March 17th, 2020. We used SARS-CoV-2 real time PCR in respiratory samples to confirm the cases. RESULTS: Fifty-four of 114 patients (47%) with confirmed COVID-19 reported anosmia. Mean age of the 54 patients was 47 (+/-16) years; 67% were females and 37% were hospitalised. The median Charlson comorbidity index was 0.70 (+/-1.6 [0-7]). Forty-six patients (85%) had dysgeusia and 28% presented with pneumonia. Anosmia began 4.4 (+/-1.9 [1-8]) days after infection onset. The mean duration of anosmia was 8.9 (+/-6.3 [1-21]) days and 98% of patients recovered within 28 days. CONCLUSIONS: Anosmia was present in half of our European COVID-19 patients and was often associated with dysgeusia. |Adult[MESH] |Aged[MESH] |Betacoronavirus/physiology[MESH] |COVID-19[MESH] |Cohort Studies[MESH] |Comorbidity[MESH] |Coronavirus Infections/*complications/*epidemiology/pathology/therapy[MESH] |Female[MESH] |France/epidemiology[MESH] |Humans[MESH] |Male[MESH] |Middle Aged[MESH] |Olfaction Disorders/*epidemiology/therapy/*virology[MESH] |Oxygen Inhalation Therapy[MESH] |Pandemics[MESH] |Pneumonia, Viral/*complications/*epidemiology/pathology/therapy[MESH] |Pneumonia/epidemiology/physiopathology/therapy/virology[MESH] |Prevalence[MESH] |Respiratory Function Tests[MESH] |Retrospective Studies[MESH] |SARS-CoV-2[MESH] |Severity of Illness Index[MESH]Features of anosmia in COVID-19 (epmc).pdf DeepDyve Pubget Overpricing